Glucocorticoids are important regulators of renal phosphate transport. This study investigates the role of alterations in renal brush border membrane (BBM) sodium gradient-dependent phosphate transport (Na-Pi cotransporter) mRNA and protein abundance in the dexamethasone induced inhibition of Na-Pi cotransport in the rat. Dexamethasone administration for 4 d caused a 1.5-fold increase in the V,.. of Na-Pi cotransport (1785±119 vs. 2759±375 pmol/5 s per mg BBM protein in control, P < 0.01), which was paralleled by a 2.5-fold decrease in the abundance of Na-Pi mRNA and Na-Pi protein. There was also a 1.7-fold increase in BBM glucosylceramide content (528±63 vs. 312±41 ng/mg BBM protein in control, P < 0.02). To determine whether the alteration in glucosylceramide content per se played a functional role in the decrease in Na-Pi cotransport, control rats were treated with the glucosylceramide synthase inhibitor, D-threo-l-phenyl-2-decanoyl-amino-3-morpholino-1-propanol (PDMP). The resultant 1.5-fold decrease in BBM glucosylceramide content (199±19 vs. 312±41 ng/mg BBM protein in control, P < 0.02) was associated with a 1.4-fold increase in Na-Pi cotransport activity (1422±73 vs. 1048±85 pmol/5 s per mg BBM protein in control, P < 0.01), and a 1.5-fold increase in BBM Na-Pi protein abundance. Thus, dexamethasone-induced inhibition of Na-Pi cotransport is associated with a decrease in BBM Na-Pi cotransporter abundance, and an increase in glucosylceramide. Since primary alteration in BBM glucosylceramide content per se directly and selectively modulates BBM Na-Pi cotransport activity and Na-Pi protein abundance, we propose that the increase in BBM glucosylceramide content plays an important role in mediating the inhibitory effect of dexamethasone on Na-Pi cotransport activity. (J. Clin. Invest. 1995. 96:207-216.)
Introduction
Glucocorticoids are important regulators of renal phosphate transport. Glucocorticoid excess, e.g., Cushing's disease, and tDr. Gross died on November 17, 1992. the administration of glucocorticoids to humans or experimental animals decreases tubular reabsorption of phosphate (1) (2) (3) . In contrast, glucocorticoid deficiency after adrenalectomy increases tubular reabsorption of phosphate (4) . The primary site of action of glucocorticoids to reduce phosphate reabsorption is the proximal tubule (5) , an effect that is independent of endogenous parathyroid hormone activity (6) . This inhibitory effect of glucocorticoids on renal tubular phosphate transport is expressed at the level of the proximal tubular apical brush border membranes (7, 8) . The decrease in sodium gradientdependent phosphate transport (Na-Pi cotransport)' results from a decrease in the V. rather than a change in the affinity for phosphate (8) . It is not known whether the decrease in the V., reflects a decrease in the number of active Na-Pi cotransport proteins or a change in the transport properties of existing Na-Pi cotransport proteins.
Studies in freshly isolated proximal tubular cells or in primary cultured renal cells indicate that glucocorticoids have a direct and selective inhibitory effect on Na-Pi cotransport demonstrating that the effect is independent of concomitant alterations in renal hemodynamics and/or other phosphate transport regulatory hormones (9) (10) . In cultured chick renal cells, dexamethasone inhibition of Na-Pi cotransport is blocked by inhibitors of transcription (actinomycin D) and translation (cycloheximide) (10) . The nature of the inhibitory proteins produced by dexamethasone is unknown. They could inhibit of Na-Pi cotransport by causing a decrease in the abundance of Na-Pi cotransport proteins. Alternatively, they might alter membrane lipid composition, since alterations in brush border membrane lipid content or lipid dynamics also regulate Na-Pi cotransport ( 11 ) . Thus, inhibitors of RNA and protein synthesis could block dexamethasone induced inhibition of Na-Pi cotransport through an effect on the synthesis and content of specific membrane lipids.
Recently the cDNA for a Na-Pi cotransport system of rat kidney cortex (NaPi-2) has been identified by expression cloning (12) . Using polyclonal antibodies raised against this renal Na-Pi cotransport system, and using the polymerase chain reaction after reverse transcription of mRNA in microdissected nephron segments, we recently demonstrated that NaPi-2-related mRNA and protein is expressed in the brush border membranes of the proximal tubules in rat kidney (13) .
The present study investigates (a) whether the inhibitory effect of dexamethasone on Na-Pi cotransport is mediated by changes in Na-Pi cotransport mRNA and protein abundance and/or a change in brush border membrane lipid composition and lipid dynamics, and (b) whether the alteration in brush border membrane lipid composition per se can directly modulate Na-Pi cotransport activity.
Methods

Experimental animals
The experiments were performed in male Sprague Dawley rats weighing 150-200 grams (Harlan Industries, Indianapolis, IN). Before study, the animals were stabilized on the control diet (0.6% Pi) for 5 d in metabolic balance cages. The rats were then treated with dexamethasone, 100 pg/ 100 gram body weight, or vehicle (deionized water), administered subcutaneously once a day for four consecutive days. On the fourth day, a 24-h urine collection was obtained. On the fifth day, the rats were anesthetized with sodium pentobarbital, blood was obtained from the inferior vena cava, and the kidneys rapidly removed and placed in an ice-cold buffer. Blood and urine samples were analyzed for inorganic phosphate by the method of Fiske and Subbarow ( 14) , and for creatinine by a creatinine autoanalyzer (Creatinine H Analyzer, Beckman, Fullerton, CA). Total urinary phosphate excretion and tubular reabsorption of phosphate were calculated by standard clearance formulae.
In experiments designed to determine the role of alteration in glucosylceramide content per se in the regulation of Na-Pi cotransport (see Results), control animals were treated with DL-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), an inhibitor of glucosylceramide synthase (15) (16) . Since previous studies have demonstrated that the circulating plasma levels of PDMP are prolonged in the presence of the cytochrome P450 inhibitor, piperonyl butoxide ( 16), the butoxide solution was administered before injection of PDMP. The piperonyl butoxide was prepared by dissolution in corn oil at a concentration of 150 mg/ml oil. On the first day of treatment, the butoxide solution was administered intraperitoneally 4 h before PDMP treatment; on days 2 to 4 of treatment, it was administered just before the PDMP injection. PDMP was prepared as an emulsion with the detergent Myrj 52 in normal saline, buffered with sodium acetate. The final concentrations were PDMP 6 mg/dl, Myrj 52 12 mg/dl, and sodium acetate 8 mg/dl. The PDMP was given intraperitoneally as a dose of 100 mg/kg body weight.
Brush border membrane isolation
The kidneys were placed in an ice-cold homogenizing buffer consisting of 300 mM mannitol, 5 mM EGTA, 0.1 mM PMSF, 16 mM HEPES, pH 7.50 with Tris. Thin slices were cut from the superficial cortex and homogenized with a Polytron homogenizer. Brush border membrane (BBM) vesicles were isolated from the resulting homogenate by differential centrifugation and Mg2+ precipitation, as previously described (17) . To minimize the potential day-to-day variations in BBM isolation procedure on the resultant measurements, each day BBM from control and dexamethasone-treated rats were isolated simultaneously. For each BBM sample the kidneys from three rats from each experimental group were pooled (n = 1). A total of 36 rats were studied in each group, resulting in n = 12 BBM samples for each experimental group. The final BBM pellet was resuspended in a 300 mM mannitol, 16 mM Hepes, 10 mM Tris, pH 7.50 buffer and was aliquoted for simultaneous measurements of (a) enzyme activity, (b) transport activity, (c) protein electrophoresis and Western blotting, (d) lipid composition, and (e) lipid fluidity.
Brush border membrane enzyme activity measurements
The purity of each BBM preparation was determined by measurement of membrane-bound specific enzyme activity, including leucine aminopeptidase (apical marker) and Na,K-ATPase (basolateral marker) in cortical homogenate and in BBM fractions as previously described ( 18) .
Enzyme activities were expressed as prmol/h per mg cortical homogenate or BBM protein. Enrichment (specific activity in BBM/specific activity in homogenate) and recovery (total activity in BBM/total activity in homogenate) were determined using the above enzymes as markers of apical and basolateral membranes. Protein was determined by the method of Lowry et al (19) using crystalline BSA as standard.
Brush border membrane transport measurements
Transport measurements were performed in freshly isolated BBM vesicles by radiotracer uptake followed by rapid millipore filtration. To measure Na+ gradient-dependent 32Pi uptake (Na-Pi cotransport), 10 M1 of BBM preloaded in an intravesicular buffer of 300 mM mannitol, 16 mM Hepes, 10 ( 11) .
To determine individual phospholipid polar head group species. An aliquot of the lipid extract was applied to thin layer chromatography plates (Silica Gel 60, E. Merck, Darmstadt, FRG) and individual phospholipids including sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol were separated by a two-dimension solvent system (24), as we have previously described (17) (18) . Phospholipid content in total and individual phospholipids was determined by measuring phosphorus content by the method of Ames and Dubin (25) .
To determine the glycosphingolipid composition. An aliquot of the lipid extract was evaporated to dryness and subjected to alkaline methanolysis. Briefly, the dried lipids were dissolved in 2 ml of chloroform.
The reaction was started by adding 1 ml of 0.21 N sodium hydroxide in methanol, continued for 1 h at 370C and terminated by adding 0.8 ml of 0.2 M acetic acid. The resultant mixture was centrifuged for 5 min at 800 grams. The upper layer was removed. The lower layer was washed with 1 ml of methanol plus 0.8 ml of water. After the same centrifugation, the lower layer was transferred into another glass tube and dried under a stream of nitrogen gas. The lipids were then chromatographed on high performance thin layer chromatography plates (HPTLC, E. Merck 5641): glucosylceramide was separated with a solvent system consisting of chloroform:methanol:water (65:25:4) on plates which were pretreated with 2.5% borax in methanol:water (1: 1). The lipid bands were visualized by impregnating the plates with a modified charring reagent (100 grams of CuSO45H2O in conc. H3PO4/water/ methanol (100:750:400) (16) . The charred TLC plates were scanned with a video densitometer. The glucosylceramide bands were quantitated by comparing the density of each spot with the density of the corresponding standard curve.
To determine the glycosphingolipid molecular species. The lipid extracts were dissolved in chloroform:methanol, 2:1, vol/vol, and partitioned into lower and upper phase GSL according to Folch et al. (26) . The lower phase GSL were put over a Unisil column and eluted with acetone:methanol, 9:1, vol/vol. After alkaline hydrolysis the samples were dried and perbenzoylated in 10% benzoyl chloride in pyridine for 16 h at 370C. The benzoylated glycolipids were then dissolved in carbon tetrachloride, and injected onto a silica gel column (Zipax, E.I. Dupont, Wilmington, DE, 2.1 mm x 50 cm) and eluted with a 13-min linear gradient of 1-20% dioxane in hexane with a flow rate of 2 ml/min (27) . Absorption was read at 230 nm. The individual GSL peaks were integrated by a Dynamax system on a Macintosh SE computer.
Brush border membrane lipid fluidity measurements BBM fluidity was determined by the steady-state and time-resolved fluorescence measurements of (a) 1,6-diphenyl-1,3,5,-hexatriene (DPH), and (b) 6-dodecanoyl-2-diethylaminonaphthalene (Laurdan) (Molecular Probes, Eugene, OR). The steady-state emission spectra of Laurdan was measured in a spectrofluorometer (SLM 4800C, Urbana, IL). Excitation wavelength was 340 am, and emission was measured at 440 nm and 490 nm. In phospholipid vesicles and in BBM the emission maximum for Laurdan is 440 nm in the gel phase and 490 nm in the liquid-crystalline phase (28) (29) . The emission spectra of Laurdan is quantitated by the generalized polarization (GP)
where 40 and 490 are the emission intensities at 440 and 490 nm, respectively (28) (29) .
The steady-state anisotropy of DPH (rDpH) was measured in the same spectrofluorometer equipped with excitation and emission polarizers. Excitation wavelength was 360 nm and emission was viewed through a KV 399 nm filter. rDpH is determined by:
In -II -In + 2II where III and I represent the intensities of the parallel and perpendicular components of the emission respectively (17 Membranes were stripped (0.1 x SSC, 0.1% SDS at 950C for 5 min) before another hybridization was performed. mRNA levels for NaPi-2 was quantitated by densitometry and normalized to the density of the corresponding GAPDH and,B-actin mRNA.
Data analysis
The data are expressed as the mean±SE. The statistical significance of the results between samples obtained from control and experimental rats was determined by the unpaired students t test or one way analysis of variance with Student-Newman Keul analysis for multiple comparisons.
Significance was accepted at the P < 0.05 level.
Results
The effect of dexamethasone on urinary phosphate excretion. Dexamethasone administration caused a significant increase in urinary excretion of Pi and a decrease in the tubular reabsorption of Pi. These occurred despite a decrease in serum Pi concentration (Table I ).
The effect ofdexamethasone on BBM enzyme activity. Dexamethasone had no effect on the activity of the apical membrane enzyme marker leucine aminopeptidase. Enrichment and recovery of leucine aminopeptidase was similar in BBM isolated from control and dexamethasone-treated rats. As previously described (36) , dexamethasone caused an increase in the activity of the basolateral membrane enzyme marker Na,K-ATPase. Enrichment and recovery of Na,K-ATPase was, however, minimal and similar in BBM isolated from control and dexamethasonetreated rats (Table II) . BBM isolated from control and dexamethasone-treated rats were, therefore, highly and similarly purified. The effect of dexamethasone on BBM transport activity. Dexamethasone caused a significant decrease in BBM Na-Pi cotransport activity. The decrease in Na-Pi-cotransport was selective as dexamethasone did not cause changes in Na-glucose or Na-proline cotransport activities (Fig. 1) . The decrease in Na-Pi cotransport in dexamethasone-treated rats was not caused by a faster dissipation of the Na' gradient via the enhanced activity of the Na/H antiporter, as, in the presence of 3 mM amiloride, Na-Pi cotransport was still significantly decreased (954±22 in dexamethasone vs. 1386±123 pmol 32Pi/5 s per mg BBM protein in control, P < 0.01).
The effect of dexamethasone on BBM Na-Pi cotransport kinetics. Kinetics of Na-Pi cotransport in the presence of 150 mM NaCl and as a function of extravesicular Pi ranging from 25 to 800 .tM Pi indicated that dexamethasone caused a decrease the V, of Na-Pi cotransport, whereas, dexamethasone did not change the affinity for Pi (Fig. 2) . Similarly, kinetics of Na-Pi cotransport in the presence of 800 uM Pi and as a function of extravesicular NaCl ranging from 0 to 150 mM NaCl indicated that dexamethasone caused a decrease in the V, of Na-Pi cotransport, whereas, dexamethasone did not change the affinity for Na, or the stoichiometry for Na-Pi cotransport (data not shown). Figure 1 . Effect of dexamethasone on BBM sodium gradient-dependent phosphate (Na-Pi), glucose (Na-Glu), and proline (Na-Pro) transport activity. The data are expressed as the mean±SE for 12 BBM in each group.
The effect of dexamethasone on renal cortical Na-Pi mRNA abundance. To determine if the Vm,, of Na-Pi cotransport was associated with a decrease in Na-Pi mRNA, RNA isolated from control and dexamethasone treated rats were analyzed by Northern blots. As illustrated in Fig. 3 , NaPi-2 mRNa shown by a 2.6-kb transcript is significantly decreased in dexamethasone treated rats. Ethidium bromide staining of the gel and rehybridization of the Northern blot with GAPDH or /3-actin cDNA probes indicate that the decrease in NaPi-2 mRNA abundance is not due to differences in RNA loading on the gels. The abundance of NaPi-2 mRNA relative to GAPDH or P-actin mRNA, determined by densitometric analysis, indicates that NaPi-2 mRNA is decreased by 2.5-fold in dexamethasone treated rats.
The effect of dexamethasone on BBM Na-Pi cotransporter abundance. To determine if the dexamethasone induced decrease in the Vma,, of Na-Pi cotransport was associated with a decrease in Na-Pi cotransporter abundance, BBM isolated from control and dexamethasone treated rats were analyzed by Western blots using the anti (NaPi-2)-antiserum. As illustrated in Fig. 4 , a strong reaction with a 80-90-kD protein bands was observed in BBM from control and dexamethasone rats. Densitometric analysis of the reaction with these protein bands showed that in BBM isolated from dexamethasone treated rats there was a 2.5-fold decrease in the staining intensity when compared to BBM isolated from control rats. The staining pattern is specific since these protein bands were not visualized in the presence of preimmune serum and were completely protected by antigenic peptide (13) . As a control the same BBM were analyzed for the presence of ecto-5 '-nucleotidase by West lin, a decrease in phosphatidylcholine, resulting in an increase in the sphingomyelin to phosphatidylcholine mole ratio (Table  IV) . Dexamethasone had no effect on phosphatidylethanolamine, phosphatidylserine, or phosphatidylinositol mole content (Table IV (Fig. 5 left) . Dexamethasone also significantly increased the fluorescence lifetime of DPH. DPH lifetime data in biological membranes is best fitted assuming a Lorentzian distribution rather than a single or multiple discrete lifetime components Figure 3 . Northern blot analysis of RNA isolated from control, dexamethasone, and PDMP treated rats. After electrophoresis RNA was transferred to membranes and hybridized sequentially with NaPi-2, GAPDH, and /3-actin cDNA probes. The mRNA bands corresponding to NaPi-2, GAPDH, and P-actin were quantitated by densitometry.
NaPi-2/GAPDH mRNA relative density (mean±SEM, n = 6:1.000±0.051 in control, 0.373±0.046 in dexamethasone, P < 0.01, and 1.010±0.066 in PDMP (P = NS compared to control). NaPi-2/1f-actin mRNA relative density (mean+SEM, n = 6:1.028±0.095 in control, 0.462±0.043 in dexemethasone, P < 0.001, and 1.037±0.130 in PDMP (P = NS compared to control). (36). There was a significant increase in the center (9.94 in control vs. 10.50 ns in dexamethasone, P < 0.01), and a significant decrease in the width (1.60 in control vs. 0.93 ns in dexamethasone, P < 0.01) of the lifetime distribution of DPH in BBM isolated from dexamethasone-treated rats (Fig. 6 A) . Dexamethasone also significantly decreased the rotational diffusion of DPH as measured by the dynamic polarization of DPH. Dexamethasone caused an increase in the limiting anisotropy, and caused decreases in the fast and slow rotational diffusion rate of DPH within the BBM lipid bilayer (Table V) .
Dexamethasone also increased the generalized polarization of the phase sensitive fluorescence probe Laurdan (Fig. 5 right) . Dexamethasone caused a significant increase in the center (4.33 in control vs. 4 .58 ns in dexamethasone, P < 0.05) and a significant decrease in the width (0.43 in control vs. 0.15 ns in dexamethasone, P < 0.01) of the lifetime distribution of Laurdan (Fig. 6 B) . The steady-state and lifetime measurements with DPH (rotational probe) and Laurdan (phase-sensitive probe), Figure 4 . Western blot analysis of BBM isolated from control, dexamethasone, and PDMP-treated rats. After SDS-polyacrylamide gel electrophoresis BBM proteins were transferred to membranes, and probed with antisera to Na-Pi cotransport system (NaPi-2) and ecto-5 '-nucleotidase (5 'NT). Protein bands corresponding to NaPi-2 and 5' NT were quantitated by densitometry. NaPi-2 relative density (mean±SEM, n = 6:1.00t0 14 therefore, indicate that dexamethasone causes a decrease in BBM lipid fluidity. The effect ofPDMP on BBM glucosylceramide content and Na-Pi cotransport activity. The administration of the glucosylceramide synthase inhibitor PDMP to control rats significantly decreased glucosylceramide content (199±19 with PDMP vs. 312±41 ng/mg BBM protein in control, P < 0.02). The effect of PDMP on glucosylceramide content was quite specific as PDMP caused no changes in BBM cholesterol, total phospholipid, sphingomyelin, or phosphatidyicholine content (Table  VI) . The effect of PDMP to lower BBM glucosylceramide content was associated with a significant increase in BBM NaPi cotransport activity (Fig. 7) . The effect of PDMP was specific and selective for Na-Pi, as PDMP did not significantly alter Na-glucose or Na-proline cotransport activities (Fig. 7) . The effect of PDMP to increase BBM Na-Pi cotransport activity was associated with a 1.5-fold increase in BBM NaPi-2 protein abundance (Fig. 4) . Interestingly, the increase in NaPi-2 protein abundance was not associated with an increase in NaPi-2 mRNA abundance (Fig. 3) . The effect of PDMP to lower BBM glucosylceramide content was also associated with an increase in BBM lipid fluidity, as reflected by a significant decrease .in the steady-state fluorescence anisotropy of DPH (Fig. 8) .
Discussion
This study demonstrates that dexamethasone selectively inhibits BBM Na-Pi cotransport activity, an effect mediated by a decrease in the V,.,. There was no change in the affinities of the transporter for Na or Pi. These results agree with previous studies also showing that the inhibitory effect of dexamethasone on NaPi cotransport is independent of endogenous parathyroid hormone activity and of dietary Pi content (6, 8) .
The decrease in V., of renal cortical BBM NaPi cotransport in dexamethasone treated rats correlated with parallel decreases in renal cortical NaPi-2 mRNA content and renal cortical BBM NaPi-2 protein abundance. The decreases in transcription and translation of Na-Pi cotransporter plays an important role in the dexamethasone induced inhibition of Na-Pi cotransport. Since in a previous study actinomycin D and cycloheximide blocked the inhibition of Na-Pi cotransport, it is possible that dexamethasone may activate a regulatory protein which then inhibits NaPi specific transcription and translation.
The decrease in the V,, of Na-Pi cotransport also correlated with increases in BBM glucosylceramide and sphingomyelin content. Dexamethasone was shown to increase the sphingomyelin content of 3T3-L1 and HeLa cells by increasing the rate of sphingomyelin synthesis from phosphatidylcholine (38, 39) . The present study is the first to determine the effect of dexamethasone on renal BBM sphingomyelin composition. We found that dexamethasone increased sphingomyelin content by 9.3%. This was paralleled by an 8.0% decrease in phosphatidylcholine content. These results are compatible with observations on many cell lines, including the kidney, that sphingomyelin is rDPH GPAURDA Lifetime ( ns ) synthesized from phosphatidylcholine by the addition of ceramide (40, 41) . Also, we and others have found that an alteration in BBM sphingomyelin content is associated with a similar but opposite change in phosphatidylcholine content (17, 18) . The net result is no overall change in the sum total of BBM sphingomyelin plus phosphatidyicholine content.
Dahiya and Brasitus had reported that dexamethasone increased rat renal cortical and medullary total neutral glycosphingolipid content (42) . In our study, we specifically measured the effect of dexamethasone on superficial cortical BBM glucosylceramide content since we were interested in correlating the effects of dexamethasone on BBM Na-Pi cotransport with the potential effects of dexamethasone on BBM glycosphingolipid composition. Our study does not determine whether the effect of dexamethasone to increase glucosylceramide content is mediated by increased rate of synthesis or decreased rate of degradation of glucosylceramide (15) . Dexamethasone enhances gluconeogenesis in rat kidney cortex (8) . Increased gluconeogenesis may increase UDP-glucose, providing increased substrate for glucosylceramide synthesis (15) , even in the absence of changes in the activities of glucosylceramide synthase or glucosylceramide /-glucosidase. These later enzymes regulate glucosylceramide synthesis and hydrolysis, respectively ( 15 ). Dahiya and Brasitus had reported that dexamethasone increased the concentration of neutral glycosphingolipids and the short chain hydroxy fatty acids of glucosylceramide. While these data are not directly comparable to those presented here in that a different strain of rats (Sherman vs. Sprague Dawley) was used and total kidney rather than cortical BBM was analyzed, the data are, nevertheless, consistent in that there appears to be an increase in the hydroxylated neutral glycosphingolipid species following dexamethasone (42) . Interestingly, in addition to the effect of increased levels of sphingomyelin, an increase in the relative amounts of the more polar hydroxylated glycosphingolipid species would also be expected to cause a decrease in membrane fluidity (43) . Our study indicates that the dexamethasone induced increase (e) downregulation of c-myc expression (44) (45) (46) (47) . In addition, glycosphingolipids may also modulate protein delivery from the endoplasmic reticulum-golgi complex to the plasma membrane. In baby hamster kidney cells, inhibition of glucosylceramide synthase with PDMP markedly decreases plasma membrane glucosylceramide content and also impairs plasma membrane delivery of the vesicular stomatitis virus G (VSV-G) protein (48). Therefore, glycophinglipids can modulate cell function by transcriptional/translational as well as posttranslational mechanisms. Our data indicates that in dexamethasone treated rats the increase in BBM glucosylceramide content is correlated with decreases in NaPi-2 mRNA and NaPi-2 protein abundance. In contrast, in PDMP treated rats the decrease in BBM glucosylceramide content is correlated with an increase in NaPi-2 protein abundance, independent of changes in NaPi-2 mRNA abundance.
Alterations in BBM lipid composition could also alter the lipid mobility and/or the lipid dynamics which could in turn modulate Na-Pi cotransport activity (11) . In our study, we found dexamethasone induced increases in BBM glucosylceramide and sphingomyelin content were associated with significant changes in steady-state anisotropy, lifetime distribution, and rotational diffusion rate of the fluorescent probe DPH, as well as significant changes in the emission spectra and lifetime of the phase-sensitive fluorescent probe Laurdan. These changes indicate that dexamethasone causes less "fluid" and/or more "ordered or gel-like" microenvironments in the BBM lipid bilayer (29) . In agreement with our previous findings (11) these changes are associated with a selective modulation of NaPi cotransport, while there are no changes in Na-glucose or Na-proline cotransport activities. The effects of increases in membrane glycosphingolipid content and/or dexamethasone administration to decrease membrane fluidity occurs in several (49) (50) (51) , but not all (52-54) cells of non-renal origin. The effect of PDMP to decrease BBM glucosylceramide content and increase BBM Na-Pi cotransport activity, on the other hand, is associated with an increase in BBM fluidity. Thus, in addition to the inverse correlation between BBM glucosylceramide content and BBM Na-Pi cotransport activity (Fig. 9) , there is also a direct correlation between BBM fluidity and BBM Na-Pi cotransport activity.
In summary, these studies indicate that dexamethasone induced decrease in the Vn,. of BBM Na-Pi cotransport is correlated with decreases in renal cortical NaPi-2 mRNA and BBM NaPi-2 protein abundance, and with an increase in BBM glycosphingolipid content. Since primary alteration in BBM glucosylceramide content selectively modulates BBM Na-Pi cotransport activity and NaPi-2 protein abundance, we propose that the dexamethasone induced increase in BBM glucosylceramide content, or a closely related glycosphingolipid, plays an important role in mediating the inhibitory effect of dexamethasone on Na-Pi cotransport activity.
